Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple fiber ease Parkinson's symptoms?

NCT ID NCT03667404

Symptom relief Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a dietary fiber called resistant maltodextrin is safe and tolerable for people with Parkinson's disease. Half of the 30 participants will take the fiber, and the other half will take a control substance. Researchers will check for side effects and see if the fiber changes gut bacteria and improves motor and non-motor symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2018

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women age ≥60 years * Diagnosis of PD based on United Kingdom PD brain bank criteria, Hoehn and Yahr stage 1-3. * Stable dose of PD medications for 30 days prior to study and for duration of study * If used, stable dose of melatonin, sedative/hypnotic or stimulant medications Exclusion Criteria: * use of other prebiotic or probiotic treatment for 30 days prior to or during the study * unstable medical or psychiatric disorder * history of diabetes mellitus or current use of medication for diabetes * cognitive impairment based on Montreal Cognitive Assessment (MoCA) \<25. * current or recent (within previous 3 weeks) use of laxatives * use of antibiotics in the past 30 days * participation in another clinical trial in the past 30 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dietary modification are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dietary modification Intestinal bacteria flora disturbance Parkinson disease

Contacts and locations

Locations

  • Northwestern University

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.